QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Doug Lakin who wrote ()	1/27/1998 1:56:00 PM
From: Jarrod W. Pakosh	of 1321

Great day today so far boys! From Investor's Digest January 30, 1998 Issue: "Analyst Michael Lorimer and associate Kathy Nassas have initiated coverage of QLT with a buy recommendation for investors with a moderate to high risk tolerance. The one and three year target prices are $23 and $42 respectively." I was researching liver cancer treatments for a friend of the family on the internet and time and time again came across photodynamic therapy mentioned as a new breakthrough treatment for cancer. ie. The Mayo Clinic: mayo.edu Encouraging that so many hospitals and cancer organizations are taking note anyway. Jarrod 8~D

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next